They first investigate the transcriptomic and mutation profiles of primary AML patients’ samples with FLT3-ITD or FLT3-ITD/D835 and found that FLT3-ITD/D835 cases were bearing co-mutations more often than FLT3/ITDs and showing higher BCL2A1 RNA expression. Here, BCL2A1 is linked to acute myeloid leukemia.